Pathology: es-BC - HER2 positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 1st Line (L1); la/mBC - HER2 positive - 2nd Line (L2);
es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | |||||||||
GeparQuinto, 2012 | PERTAIN, 2018 | CLEOPATRA, 2012 | PUFFIN, 2020 | SYSUCC-002, 2022 | ExteNET, 2016 | NALA (brain metastases), 2020 | NALA, 2020 | HER2CLIMB (patients with brain metastases), 2020 | HER2CLIMB, 2020 | ||
neratinib plus capecitabine | 2 | T1 | T1 | ||||||||
tucatinib plus trastuzumab plus capecitabine | 2 | T1 | T1 | ||||||||
pertuzumab plus trastuzumab plus docetaxel | 2 | T1 | T1 | ||||||||
trastuzumab plus endocrine therapy | 1 | T1 | |||||||||
pertuzumab plus trastuzumab | 1 | T1 | |||||||||
neratinib | 1 | T1 | |||||||||
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | 1 | T1 | |||||||||
trastuzumab plus chemotherapy | 0 | T0 | |||||||||
lapatinib plus capecitabine | 0 | T0 | T0 | ||||||||
trastuzumab plus capecitabine | 0 | T0 | T0 | ||||||||
trastuzumab | 0 | T0 | |||||||||
trastuzumab plus docetaxel | 0 | T0 | T0 | ||||||||
placebo | 0 | T0 | |||||||||
lapatinib plus epirubicin and cyclophosphamide followed by docetaxel | 0 | T0 |